Evidence map›Paper›PMID 23469203›Full record

ArticlePloS one2013

Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer.

Kun Li, Steven J Dias, Agnes M Rimando, Swati Dhar, Cassia S Mizuno, Alan D Penman, Jack R Lewin, Anait S Levenson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Dietary polyphenols in prevention and treatment of prostate cancer.International journal of molecular sciences · 2015
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Pterostilbene in Cancer Therapy.Antioxidants (Basel, Switzerland) · 2021
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kun LiCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi, United States of America.
Steven J Dias
Agnes M Rimando
Swati Dhar
Cassia S Mizuno
Alan D Penman
Jack R Lewin
Anait S Levenson
University of Mississippi Medical Center · USAgricultural Research Service · USUnited States Department of Agriculture · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

The development of natural product agents with targeted strategies holds promise for enhanced anticancer therapy with reduced drug-associated side effects. Resveratrol found in red wine, has anticancer activity in various tumor types. We reported earlier on a new molecular target of resveratrol, the metastasis-associated protein 1 (MTA1), which is a part of nucleosome remodeling and deacetylation (NuRD) co-repressor complex that mediates gene silencing. We identified resveratrol as a regulator of MTA1/NuRD complex and re-activator of p53 acetylation in prostate cancer (PCa). In the current study, we addressed whether resveratrol analogues also possess the ability to inhibit MTA1 and to reverse p53 deacetylation. We demonstrated that pterostilbene (PTER), found in blueberries, had greater increase in MTA1-mediated p53 acetylation, confirming superior potency over resveratrol as dietary epigenetic agent. In orthotopic PCa xenografts, resveratrol and PTER significantly inhibited tumor growth, progression, local invasion and spontaneous metastasis. Furthermore, MTA1-knockdown sensitized cells to these agents resulting in additional reduction of tumor progression and metastasis. The reduction was dependent on MTA1 signaling showing increased p53 acetylation, higher apoptotic index and less angiogenesis in vivo in all xenografts treated with the compounds, and particularly with PTER. Altogether, our results indicate MTA1 as a major contributor in prostate tumor malignant progression, and support the use of strategies targeting MTA1. Our strong pre-clinical data indicate PTER as a potent, selective and pharmacologically safe natural product that may be tested in advanced PCa.

Indexed as

AcetylationAnimalsAntineoplastic Agents, PhytogenicDisease ProgressionEpigenesis, GeneticGene Expression Regulation, NeoplasticGenes, ReporterHumansLuciferasesMaleMi-2 Nucleosome Remodeling and Deacetylase ComplexMiceNeoplasm MetastasisProstatic NeoplasmsRepressor ProteinsResveratrolAntineoplastic Agents, PhytogenicLuciferasesMi-2 Nucleosome Remodeling and Deacetylase ComplexMta1 protein, mousepterostilbeneRepressor ProteinsResveratrolStilbenesTrans-ActivatorsTranscription FactorsTumor Suppressor Protein p53

Identifiers

PMID23469203
PMCPMC3586048
OpenAlexW2121244179

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.